REVIEW | doi:10.20944/preprints202305.0558.v1
Subject: Medicine And Pharmacology, Epidemiology And Infectious Diseases Keywords: Monkeypox outbreak; Public health; emergency; Peru
Online: 9 May 2023 (04:11:23 CEST)
Monkeypox is a zoonotic illness caused by the Orthopoxvirus monkeypox virus (MPXV). Since 1970, outbreaks of MPXV have occurred in several Sub-Saharan African countries. However, from May 2022 to April 2023, recent outbreaks of MPXV occurred in several countries outside of Africa, and these cases quickly spread to over 100 non-endemic countries on all continents. Because of this, in July 2022, World Health Organization declared monkeypox a Public Health Emergency of International. MPXV disproportionately affects men who have sex with men and members of the HIV-infected population. The current strategy for control and pre-exposure prophylaxis or post-exposure prophylaxis for people at high risk is vaccination. In this context, Peru has the fourth-highest number of MPXV cases in Latin America. Because of this, in this review, we describe public health indicators in Peru and reflect on the COVID-19 pandemic so that health authorities can join forces to identify and control MPXV transmission routes.
REVIEW | doi:10.20944/preprints202210.0022.v2
Subject: Biology And Life Sciences, Virology Keywords: monkeypox; risk; elimination; epidemiology; outbreak; prediction
Online: 14 November 2022 (09:43:24 CET)
Human monkeypox, caused by monkeypox virus, has spread unprecedentedly to more than 100 countries since May 2022. Here we summarized the epidemiology of monkeypox through a literature review and elucidated the risks and elimination strategies of this outbreak mainly based on the summarized epidemiology. We demonstrated that monkeypox virus became more contagious and less virulent in 2022, which could result from the fact that the virus entered a special transmission network favoring close contacts (i.e., sexual behaviors of men who have sex with men outside Africa) and the possibility that the virus accumulated a few adaptive mutations. We gave the reasons to investigate whether cattle, goats, sheep, and pigs are susceptible to monkeypox virus and whether infection with monkeypox virus could be latent in some primates. We listed six potential scenarios for the future of the outbreak (e.g., the outbreak could lead to endemicity outside Africa with increased transmissibility or virulence). We also listed multiple factors aiding or impeding the elimination of the outbreak. We showed that the control measures strengthened worldwide after the World Health Organization declared the outbreak a public health emergency of international concern (PHEIC) could eliminate the outbreak in 2022. We clarified eight strategies, i.e., publicity and education, case isolation, vaccine stockpiling, risk-based vaccination or ring vaccination, importation quarantine, international collaboration, and laboratory management, for the elimination of the outbreak.
REVIEW | doi:10.20944/preprints202208.0128.v1
Subject: Biology And Life Sciences, Virology Keywords: monkeypox, transmission, outbreak, atypical presentation
Online: 8 August 2022 (03:57:03 CEST)
An ongoing monkeypox outbreak in non-endemic countries has resulted in the declaration of a Public Health Emergency of International Concern by the World Health Organization (WHO). Though monkeypox has long been endemic in regions of Sub-Saharan Africa, relatively little is known about its ecology, epidemiology, and transmission. Here, we consider the relevant research on both monkeypox and smallpox, a close relative, to make inferences about the current outbreak. Undetected circulation, combined with atypical transmission and case presentation, including mild and asymptomatic disease, have led to the spread of monkeypox in non-endemic regions. Broader availability of diagnostics, enhanced surveillance, and targeted education, combined with a better understanding of the routes of transmission, are critical to identify at-risk populations and design science-based countermeasures to control the current outbreak.
COMMUNICATION | doi:10.20944/preprints202206.0172.v3
Subject: Computer Science And Mathematics, Information Systems Keywords: Monkeypox; monkey pox; Twitter; Dataset; Tweets; Social Media; Big Data; Data Mining; Data Science
Online: 25 July 2022 (09:41:19 CEST)
BRIEF REPORT | doi:10.20944/preprints202208.0544.v1
Subject: Biology And Life Sciences, Virology Keywords: monkeypox; infection; healthcare
Online: 31 August 2022 (10:20:23 CEST)
We performed an epi and molecular characterization of two healthcare workers MPXV occupational infection. Five days after the sampling collection, nurses developed typical MPXV infection symptoms. Infection was confirmed by qPCR and whole genome sequencing. The most likely transmission route was through contact with fomites in the patient belonging/house.
REVIEW | doi:10.20944/preprints202207.0232.v1
Subject: Medicine And Pharmacology, Pharmacology And Toxicology Keywords: Monkeypox; Vaccine; Outbreak
Online: 15 July 2022 (12:12:58 CEST)
(1) Background: The monkeypox virus (MPV) is a double-stranded DNA virus belonging to the Poxviridae family, Chordopoxvirinae subfamily, and Or-thopoxvirus genu. It was called monkeypox because it was first discovered in monkeys, in a Danish laboratory, in 1958. However, the actual reservoir for MPV is still unknown. (2) Methods & Results: We have reviewed the existing literature on the options for Monkeypox virus. There are three available vaccines for orthopoxviruses: ACAM2000, JYNNEOS, and LC16, with the first being a replicating vaccine and the latter being non or minimally replicating. (3) Conclusions: Smallpox vaccinations previously provided coincidental im-munity to MPV. ACAM2000(a live‐attenuated replicating vaccine) and JYNNEOS (a live‐attenuated, non-replicating vaccine) are two US FDA‐approved vaccines that can prevent monkeypox. However, ACAM2000 may cause serious side effects, including cardiac problems, whereas JYNNEOS is associated with fewer com-plications. The recent outbreaks across the globe have once again highlighted the need for constant monitoring and the development of novel prophylactic and therapeutic modalities. Based on available data, there is still a need to develop an effective and safe new generation of vaccines specific for monkeypox that are killed or mRNA before monkeypox is declared a pandemic.
REVIEW | doi:10.20944/preprints202303.0304.v1
Subject: Biology And Life Sciences, Virology Keywords: Monkeypox, , Nigeria, MPXV, Epidemiology, Spillover
Online: 16 March 2023 (10:43:53 CET)
The emergence and re-emergence of infectious diseases caused by viruses continue to be a major public health concern globally, affecting both humans and animals. One such disease is monkeypox, a zoonotic infection caused by the monkeypox virus (MPXV) that has recurred in sub-Saharan Africa over several decades. Notably, the 2022 outbreak of monkeypox in Nigeria follows a deadly outbreak in 2017, which was preceded by the disease's first recorded outbreak in 1978. Epidemiological investigations in 2017 showed no apparent link between human monkeypox cases and the outbreak that year, indicating the potential existence of multiple sources of the virus and limited human-to-human transmission. This underscores the presence of an alternative ecological niche in humans. Furthermore, in some communities in Nigeria, monkeys are regarded as sacred and not hunted or consumed, leading to their proliferation and increased likelihood of MPXV transmission. This mini-review focuses on the occurrence, epidemiological distribution, geographical distribution, endemicity, and possible solutions to reduce the spread of human monkeypox in Nigeria. The implications of this reemergence and the need for effective public health measures to prevent and control outbreaks of monkeypox are also discussed.
REVIEW | doi:10.20944/preprints202206.0036.v1
Subject: Medicine And Pharmacology, Epidemiology And Infectious Diseases Keywords: Monkeypox; prevention; treatment; endemic; transmission
Online: 2 June 2022 (16:18:05 CEST)
Monkeypox virus was named so because of its detection in monkeys in 1958. It belongs to the same family as smallpox and chickenpox viruses. There had been numerous outbreaks of this malady initially in the African continent and other parts of the world. The simultaneous spread in nineteen countries in 2022 has raised some serious concerns.Monkeypox is no more a rare disease and has the potential for bioweapon use. We discuss the various ways to prevent its spread, treatment options available, diagnosis, and differentiation from other closely related diseases. We also discuss if the present outbreak could be a bioattack or if this disease is here to stay.The literature suggests that we can effectively manage Monkeypox because of the availability of drugs and vaccination against smallpox. There is also a need for active surveillance against the new resistant recombinant viral strains. The possibility of this outbreak being a bioattack seems remote, although there are questions about the transmission which still need to be answered.
ARTICLE | doi:10.20944/preprints202212.0562.v1
Subject: Medicine And Pharmacology, Immunology And Allergy Keywords: Monkeypox vaccine; vaccine willingness; healthcare workers
Online: 29 December 2022 (14:35:18 CET)
Early experience with Covid-19 shows that vaccines can be the most effective way of preventing the spread of infection. However, vaccine hesitancy is among the most significant hurdles in preventing the spread of novel infections. Monkeypox (MPX) has already been declared a global health emergency by WHO. Thus, there is an urgent need to understand the MPX vaccine willingness in various population groups. In this cross-sectional study, an online survey was conducted among Saudi healthcare workers (HCWs) to understand the monkeypox vaccine willingness in healthcare workers in Saudi Arabia. Saudi has already confirmed multiple MPX cases, and thus it is essential to initiate timely protective measures, including vaccination. The study had 743 respondents. The study found that among Saudi HCWs, 52.7% were willing to receive the MPX vaccine. The study found that sociodemographic factors had a small impact on vaccine willingness. However, early experience with vaccination had a significant impact. Thus, more than 70% who had influenza or COVID-19 vaccine were willing to receive the MPX vaccine. Some of the most significant concerns influencing vaccine acceptability were the safety and efficacy of the vaccine. Hence, it is strongly recommended to focus on disseminating information regarding the safety and efficacy of the MPX vaccine.
REVIEW | doi:10.20944/preprints202211.0052.v1
Subject: Biology And Life Sciences, Virology Keywords: Monkeypox; MPXV; emergence; wild rodents; zoonoses
Online: 2 November 2022 (09:41:59 CET)
Monkeypox virus (MPXV), causing zoonotic diseases in humans, is a member of Orthopoxvirus under Poxviridae family. The virus was first reported in monkeys in 1959 in Denmark and in humans in 1970 in the Congo. Outside Africa, the virus first appeared in the USA in 2003 and since then occurred sporadically. The virus reemerged in 2017 and now spreading globally. African wild rodent mammals are thought to be the reservoir of MPXV. Exotic trade of animals and international travel favors the dissemination of MPXV. Genetic analysis shows two clades of the MPXV. Smallpox vaccine shows cross-protection and people who never in contact with Orthopoxvirus affected more than exposed ones. Fever, muscle pain, headache, and vesicle formation are the dominant clinical sign. Guarnieri-like inclusions and Ballooning degenerations are important pathognomic lesion of MPXV. It may produce case fatality rate up to 11%. Genetic materials alterations may favor the reemergence of the virus. The continuing occurrence over 73437 cases in 109 countries shows that MPXV can spread among humans competently and can be a serious issue of global public health concern. Here, we summarize the existing knowledge about re-emergence and insights into MPXV which will be of useful to curb its occurrence.
REVIEW | doi:10.20944/preprints202207.0314.v1
Subject: Biology And Life Sciences, Virology Keywords: sexual transmission; monkeypox; emerging; global; epidemic
Online: 21 July 2022 (08:08:40 CEST)
Monkeypox is a rare disease which is rising nowadays in different countries since the first case in the UK was diagnosed on May 6, 2022, by the United Kingdom (UK) Health Security Agency. Then more than 12,500 cases were identified in over 68 countries up to July 18, 2022. In endemic areas, the monkeypox virus (MPXV) is commonly transmitted through zoonosis, while in non-endemic regions, it is spread through human-to-human transmission. Symptoms can include flu-like symptoms, rash, or sores in hands, feet, genitalia, or anus. In addition, people who did not take the smallpox vaccine were more liable to be affected than others. The exact pathogenesis and mechanisms are still unclear; however, most identified cases are reported in men who have sex with other men (MSM). According to the CDC, transmission can happen with any sexual or non-sexual contact with the infected person. However, a recent pooled meta-analysis reported that sexual contact is involved in more than 91% of the cases. Also, it is the first time that semen analysis for many patients has shown positive monkeypox virus DNA. Therefore, in this review, we will describe transmission methods for MPXV while focusing mainly on potential sexual transmission and associated sexually transmitted infections. We will also highlight the preventive measures that can limit the spread of the diseases in this regard.
REVIEW | doi:10.20944/preprints202207.0075.v1
Subject: Biology And Life Sciences, Virology Keywords: monkeypox; zoonosis; emerging viruses; 2022 MPX outbreak
Online: 5 July 2022 (13:43:09 CEST)
The global vaccination programme against smallpox (SPX) led to its successful eradication and averted millions of deaths. Monkeypox (MPX) is a close relative of SPX. Due to their antigenic similarity, SPX vaccines cross-protect against MPX. However, over 70% of people living today were never vaccinated. Symptoms of MPX infection include fever, head and muscle ache, lymphadenopathy and a characteristic rash that develops into papules, vesicles and pustules which eventually scab over and heal. MPX is less often fatal (case fatality rates range from less than 1% to up to 11%) than SPX (up to 30%). MPX is endemic in sub-Saharan Africa, infecting wild animals and causing zoonotic outbreaks. Exotic animal trade and international travel combined with the increasing susceptibility of the human population due to halted vaccination facilitated the spread of MPX to new areas. The ongoing outbreak with over 6500 confirmed cases in >50 countries between May and July 2022 shows that MPX can significantly spread between people, and may thus become a serious threat to public health with global consequences. Here, we summarize the current knowledge about this re-emerging virus, discuss available strategies to limit its spread and pathogenicity and evaluate its risk to the human population.
CASE REPORT | doi:10.20944/preprints202302.0506.v1
Subject: Medicine And Pharmacology, Epidemiology And Infectious Diseases Keywords: atypical; coinfection; Hepatitis B; human immunodeficiency virus; monkeypox
Online: 28 February 2023 (04:51:43 CET)
Mpox (monkeypox) is a zoonotic disease that has been endemic in African countries for decades, with a recent outbreak in several countries around the world. A 39-year-old male with HIV-HBV coinfection and poor adherence to antiretroviral treatment, who was severely immunocompromised and had a concurrent diagnosis of Mpox infection, presented to our hospital with disseminated dermatosis (over 350 lesions), perianal ulcers, odynophagia, oral intolerance, diarrhea, and soft-tissue bacterial superinfection of the lower extremities. Laboratory results were consistent with HBV infection, with an absolute CD4 cell count of 40 cells/uL and a positive PCR result for Mpox. An abdominopelvic CT scan showed evidence of severe proctitis and perineal soft-tissue infection. After 65 days of Mpox PCR, new lesions in the vesicular stage continued to appear, eventually developing hemodynamic instability and sepsis, resulting in a fatal outcome. Our case highlights the importance of intentionally looking for risk factors such as HIV/HBV coinfection and evaluating immune status (CD4 cell count) in patients with severe Mpox infection because it could be related to higher mortality.
REVIEW | doi:10.20944/preprints202207.0300.v1
Subject: Medicine And Pharmacology, Epidemiology And Infectious Diseases Keywords: poxviruses; Variola; smallpox; Monkeypox; Vaccinia; Orf; Molluscum; Tanapox
Online: 20 July 2022 (10:05:05 CEST)
Poxviridae have been successful pathogens throughout recorded history, infecting humans among a variety of other hosts. Although eradication of the notorious smallpox has been a globally successful healthcare phenomenon, the recent emergence of Monkeypox virus, also belonging to the Orthopoxvirus genus and causing human disease, albeit milder than smallpox, is a cause of significant public health concern. The ongoing outbreak of monkeypox, demonstrating human-human transmission, in previously non-endemic countries, calls for critical need into further research in the areas of viral biology, ecology and epidemiology to better understand, prevent and treat human infections. In the wake of these recent events, it becomes important to revisit poxviral infections, their pathogenesis and ability to cause infection across multiple non-human hosts and leap to a human host. The poxviruses that cause human diseases include Monkeypox virus, Molluscum contagiosum virus and Orf virus. In this review we summarize the current understanding of various poxviruses causing human diseases, provide insights into their replication and pathogenicity, disease progression and symptoms, preventive and treatment options and their importance in shaping modern medicine through application in gene therapy, oncolytic viral therapies for human cancers or as poxvirus vectors for vaccines.
ARTICLE | doi:10.20944/preprints202212.0415.v1
Subject: Social Sciences, Media Studies Keywords: stigma; news frame; monkeypox; COVID-19; The Washington Post; online news
Online: 22 December 2022 (03:42:16 CET)
Abstract: Background: Stigma in health can result in a broad range of vulnerabilities and risk for patients and healthcare providers. The media plays a role in people’s understanding of health and stigma is socially constructed through many communication channels including via media framing. Among health issues that were affected by stigma recently were the Monkeypox and Covid-19. Objectives: This research aims to examine how The Washington Post framed stigma around mon-keypox and COVID-19. Guided by the framing theory and stigma theory, online news coverage for monkeypox and COVID-19 were analyzed to understand the construction of social stigma through the media reporting. Methods: This research employed a qualitative content analysis to compare news framing in The Washington Post online news regarding monkeypox and COVID-19. Results: Based on endemic, reassurance, and sexual transmission frames, the The Washington Post predominantly defined Africa as the source of the disease, blames gay communities, and empha-sizes no need to worry about the spread of the monkeypox virus. For the COVID-19 coverage, The Washington Post described China as the source of the coronavirus and constructs the image of panic towards the spread of the virus. Conclusions: The shifts in stigma discourse essentially manifest racism, xenophobia, and sexism in public health. This research affirms that the media reinforces stigma phenomenon in health through framing and offers constructive suggestions for mitigating this issue.
REVIEW | doi:10.20944/preprints202208.0218.v1
Subject: Medicine And Pharmacology, Epidemiology And Infectious Diseases Keywords: Public Health Emergency; Sexual Health; Monkeypox; Smallpox; JYNNEOS; ACAM2000; Tecovirimat; Brincidofovir
Online: 11 August 2022 (11:46:12 CEST)
Monkeypox, once a rare zoonotic disease, was endemic to some African countries since its original identification among humans in 1970. Since then, cases in non endemic regions were linked to returning travelers or those who had contact with transported animals. The causative agent, Monkeypox virus, belongs to Orthopoxviruses, the same family as Variola; the causative organism for smallpox. Although most Monkeypox outbreaks until recently were linked to zoonotic transmission, secondary human-human transmission in smallpox unvaccinated individuals was observed in a small proportion of overall cases. Smallpox was declared eradicated in 1980 and since its eradication, monkeypox virus is the most significant poxvirus to cause human disease. The 2022 monkeypox outbreak marks a significant paradigm shift in the human and poxvirus association, with new modes of transmission, concerns of viral evolution and entrenchment as a sexually transmitted disease. Monkeypox clinically resembles smallpox but is far milder. At this time there are no approved therapies for monkeypox and antiviral agents effective against smallpox are being utilized. Additionally, preventive strategies being utilized include smallpox vaccination like JYNNEOS and ACAM2000. In this narrative review, we discuss the virology, epidemiology, transmission, clinical manifestations, diagnosis, management and prevention strategies associated with monkeypox.
ARTICLE | doi:10.20944/preprints202206.0392.v1
Subject: Biology And Life Sciences, Biology And Biotechnology Keywords: Multi Epitope; monkeypox virus (MPXV); Vaccine; Immunoinformatics; In silico; Molecular docking
Online: 29 June 2022 (03:43:30 CEST)
Background: While mankind is still dealing with the COVID-19 pandemic, on May 7, 2022, a case of monkeypox virus (MPXV) has been reported to the WHO. Monkeypox is a viral zoonotic disease with characteristics comparable to those seen in smallpox cases in the past. It has been a public health threat, particularly in Africa, but recently have been circulating the world, consequently, may become a global public health threat in a very short period. Thus, the current work was planned and then constructed a multi-epitope vaccine that can evoke an immunological response against MPXV utilizing cell surface-binding protein as a target in order to develop a novel vaccine that is both safe and almost free of side effects. Results: The proposed vaccine composed of 304 amino acids and was shown to be antigenic in Vaxijen server (0. 5311) and nonallergenic in AllerTop server. The 3D structure of the designed vaccine is predicted, refined and validated by various in silico tools to assess the stability of the vaccine. Moreover, solubility of the vaccine construct was found greater than the average solubility provided by protein-Sol server indicating the solubility of the vaccine construct. Moreover, the most promising epitopes bound to MHC I and MHC II alleles were found having good binding affinities with low energies ranging between ₋7.0 - ₋8.1kcal/mol. Conclusion: We conclude from our research that the cell surface-binding protein is one of the primary proteins involved in MPXV pathogenesis. The most promising epitopes were selected using a rigorous procedure and used for vaccine design. As a result, our study will aid in the development of appropriate therapeutics and prompt the development of future vaccines against MPXV, which could serve as an important milestone in the production of an antiviral vaccine against MPXV.
ARTICLE | doi:10.20944/preprints202210.0302.v1
Subject: Biology And Life Sciences, Virology Keywords: poxviruses; monkeypox virus; envelope proteins; drug repurposing; bioactive phytochemicals; molecular docking, molecular simulation
Online: 20 October 2022 (09:32:02 CEST)
The monkeypox virus (MPXV) has become a major threat due to the increasing global caseload and the ongoing multi-country outbreak in non-endemic territories. Due to limited research in this avenue and the lack of intervention strategies, the present study was aimed to virtually screen bioactive phytochemicals against envelope proteins of MPXV via rigorous computational approaches. Molecular docking and molecular dynamic (MD) simulations were used to investigate the binding affinity of 12 phytochemicals against three envelope proteins of MPXV, viz., D13, A26, and H3. Silibinin, oleanolic acid, and ursolic acid were computationally identified as potential phytochemicals that showed strong binding affinity towards all the tested structural proteins of MPXV through molecular docking. The stability of the docked complexes was also confirmed by MD simulations. ADME analysis also computationally confirmed the drug-like properties of the phytochemicals, thereby asserting their suitability for consumption. Hence, this study envisions the candidature of bioactive phytochemicals as promising inhibitors against the MPXV, serving as template molecules that could further be experimentally evaluated for their efficacy against monkeypox.
REVIEW | doi:10.20944/preprints202210.0347.v1
Subject: Medicine And Pharmacology, Pharmacology And Toxicology Keywords: monkeypox virus; infection; treatment; antiviral; drug; management; public health emergency; tecovirimat; cidofovir; bibliometric analysis
Online: 24 October 2022 (03:38:12 CEST)
Monkeypox virus infection is a recognized public health emergency. Little research has been done on treatment options for this disease. Until recently, there was not a single published work describing the usage of specific drugs in human patients with monkeypox virus infection. This paper gives the first bibliometric analysis of monkeypox treatment options based on data available on PubMed and Scopus. It also reviews the specific drugs used in the treatment of monkeypox. That includes data on Tecovirimat, Cidofovir, Brincidofovir, and Vaccinia Immune Globulin. Tecovirimat is a promising option in progressive disease in terms of efficacy and safety. However, Brincidofovir has been associated with discontinuation of treatment. Cidofovir is also not the preferred drug among physicians. Currently, Tecovirimat can be further used for the management of aggravating cases. More studies should be conducted on Tecovirimat to treat this condition, mainly through controlled trials.
REVIEW | doi:10.20944/preprints202305.0376.v1
Subject: Public Health And Healthcare, Public Health And Health Services Keywords: monkeypox; One Health; Big Data analytics; deep learning; blockchain; cybersecurity; vaccine; sexually transmitted diseases; HIV
Online: 6 May 2023 (04:50:56 CEST)
World Health Organization (WHO) has announced the monkeypox (MPX) epidemic a global public health emergency due to its re-emergence, remarkable increase in the number of MPX cases worldwide, and its potential spread. This paper introduces the symptoms, complications, and features of MPX; its transmission, diagnosis and testing, vaccines and treatment; MPX and sexually transmitted diseases, especially the human immunodeficiency virus (HIV); possible natural hosts or reservoirs of the monkeypox virus (MPXV). A useful tool for MPX and surgical safety recommendations are presented. The challenges in fighting the MPX epidemic, One Health strategy, and future research are discussed.
COMMUNICATION | doi:10.20944/preprints202303.0453.v1
Subject: Social Sciences, Media Studies Keywords: COVID-19; MPox; Twitter; Big Data; Data Mining; Data Analysis; Sentiment Analysis; Data Science; Social Media; Monkeypox
Online: 27 March 2023 (08:39:28 CEST)
Mining and analysis of the Big Data of Twitter conversations have been of significant interest to the scientific community in the fields of healthcare, epidemiology, big data, data science, computer science, and their related areas, as can be seen from several works in the last few years that focused on sentiment analysis and other forms of text analysis of Tweets related to Ebola, E-Coli, Dengue, Human papillomavirus (HPV), Middle East Respiratory Syndrome (MERS), Measles, Zika virus, H1N1, influenza-like illness, swine flu, flu, Cholera, Listeriosis, cancer, Liver Disease, Inflammatory Bowel Disease, kidney disease, lupus, Parkinson's, Diphtheria, and West Nile virus. The recent outbreaks of COVID-19 and MPox have served as "catalysts" for Twitter usage related to seeking and sharing information, views, opinions, and sentiments involving both these viruses. While there have been a few works published in the last few months that focused on performing sentiment analysis of Tweets related to either COVID-19 or MPox, none of the prior works in this field thus far involved analysis of Tweets focusing on both COVID-19 and MPox at the same time. With an aim to address this research gap, a total of 61,862 Tweets that focused on Mpox and COVID-19 simultaneously, posted between May 7, 2022, to March 3, 2023, were studied to perform sentiment analysis and text analysis. The findings of this study are manifold. First, the results of sentiment analysis show that almost half the Tweets (the actual percentage is 46.88%) had a negative sentiment. It was followed by Tweets that had a positive sentiment (31.97%) and Tweets that had a neutral sentiment (21.14%). Second, this paper presents the top 50 hashtags that were used in these Tweets. Third, it presents the top 100 most frequently used words that are featured in these Tweets. The findings of text analysis show that some of the commonly used words involved directly referring to either or both viruses. In addition to this, the presence of words such as "Polio", "Biden", "Ukraine", "HIV", "climate", and "Ebola" in the list of the top 100 most frequent words indicate that topics of conversations on Twitter in the context of COVID-19 and MPox also included a high level of interest related to other viruses, President Biden, and Ukraine. Finally, a comprehensive comparative study that involves a comparison of this work with 49 prior works in this field is presented to uphold the scientific contributions and relevance of the same.